The Novo Nordisk head-and-shoulders pattern is taking shape, with a target price of $97. While the long-term outlook remains bullish, the hype around weight loss drugs is cooling off due to increasing competition and growing awareness of potential unknown side effects.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。